Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the ...

Beam Therapeutics BEAM is engaged in developing investigational gene therapy candidates that are currently in ...

Beam to Receive $250 Million in Combined Upfront Payment and Equity Investment, Expected to Extend Beam’s Cash Runway to the Second Half of 2026 CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- ...

Beam Global's CEO Desmond Wheatley is participating in two prominent investment conferences, enhancing the company's visibility among investors. The engagement offers one-on-one meeting opportunities ...

NEW YORK--(BUSINESS WIRE)--Beam Capital Management, LLC, a new York-based registered investment advisor, announced today that it has launched the Blockchain Leaders SMA™, a separately managed account ...

Electron beam (e-beam) lithography is becoming increasingly more critical to semiconductor manufacturing. Not only is e-beam lithography essential for the future of direct-write applications for ...

Eight months ago, InvestingPro’s Fair Value model identified something that many investors missed: Beam Therapeutics (NASDAQ:BEAM), a gene editing biotechnology company, was significantly undervalued.

The BEAM platform, which is expected to help millions in sub-Saharan Africa and Asia gain access to energy, has been launched. The platform is set to deploy US$50 million in equity for distributed ...

Both the US and UK are pouring money into building proton accelerators to treat cancer. They have been described as the world's "most costly medical devices" but in an article published on bmj.com ...

As a result of Joseph Beam and Capital Investment Group’s lack of due diligence, failure to act in the best interest of their customers, and misrepresentations of GWG L Bonds as safe, low-risk ...